Pre-market hot trades in US stocks: BitMine Immersion Tech up 3.11% in pre-market
I'm LongbridgeAI, I can summarize articles.BitMine Immersion Tech pre-market up 3.11%; Scage Future pre-market up 200.00%; Basel Medical pre-market up 60.99%; Calidi Biotherapeutics pre-market up 55.22%
Pre-market Hot Trades in US Stocks
BitMine Immersion Tech is up 3.11% in pre-market trading. Based on recent important news:
-
On June 30, Bitmine Immersion Technologies announced the completion of a $250 million private placement, planned for its Ethereum financial strategy, with the stock price rising 41.15% in pre-market.
-
On July 1, the company announced its Ethereum financial strategy, with the stock price soaring 40.5% in pre-market.
-
On July 4, the stock price surged again by 130.8% due to the market's positive response to the company's Ethereum strategy.
Top Gainers in Pre-market US Stocks
Scage Future is up 200.00% in pre-market trading. Based on recent important news:
-
On May 21, during JP Morgan's Investor Day event, Jamie Dimon pointed out the complacency in the market, with investors favoring call options, anticipating a market rise.
-
On May 19, Li Ming, Vice Chairman of the Securities Regulatory Commission, stated that A-share valuations are low, encouraging restructuring to enhance market vitality.
-
On May 11, the central bank established re-lending for service consumption and elderly care, supporting financial institutions to increase support for key areas.
Basel Medical is up 60.99% in pre-market trading. Based on recent important news:
-
On June 27, Basel Medical received a lock-up period waiver, paving the way for potential strategic financing, with the stock price soaring 60.99%.
-
On June 26, Basel Medical announced plans for strategic financing, enhancing market expectations and driving the stock price up.
-
On May 29, Basel Medical reaffirmed its strong financial position, stabilizing investor confidence.
Calidi Biotherapeutics is up 55.22% in pre-market trading. Based on recent key news:
-
On July 8, Calidi Biotherapeutics announced its mention in an editorial published by NetworkNewsWire, increasing market attention and leading to a significant rise in stock price.
-
On July 7, the company launched a new biotherapeutic product, with positive market response driving the stock price further up.
-
On July 6, industry analysts gave positive evaluations of Calidi's future growth potential, boosting investor confidence
